Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.98M | -5.30M | -4.68M | -6.28M | -8.14M |
| Total Depreciation and Amortization | -- | -- | -- | 4.50K | 4.50K |
| Total Amortization of Deferred Charges | 292.80K | 292.80K | 396.50K | 517.40K | 785.80K |
| Total Other Non-Cash Items | 365.00K | 70.30K | 492.20K | -2.76M | 1.25M |
| Change in Net Operating Assets | -433.20K | -725.80K | -1.06M | 258.10K | 576.80K |
| Cash from Operations | -6.76M | -7.13M | -6.33M | -9.73M | -7.00M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.78M | -2.56M | -2.26M | -1.01M | 4.46M |
| Cash from Investing | -3.78M | -2.21M | -1.91M | -664.60K | 4.81M |
| Total Debt Issued | 5.50M | 2.75M | 2.48M | 2.48M | 475.00K |
| Total Debt Repaid | -2.63M | -2.50M | -2.50M | -2.11M | -550.00K |
| Issuance of Common Stock | 3.32M | 3.32M | 3.32M | 3.32M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 4.56M | 4.56M | 4.56M | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.75M | 9.28M | 9.01M | 4.83M | 1.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -115.80K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | -- | -- | -- |
| Net Change in Cash | 213.00K | -62.90K | 772.90K | -5.56M | -1.23M |